Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05652335 · ClinicalTrials.gov registry record · Phase 1

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

A Phase 1 study of Relapsed or Refractory Multiple Myeloma and Previously Treated Amyloid Light-chain (AL) Amyloidosis, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 1
Development phase
180
Enrollment target
20
Study locations

NCT05652335 is a Phase 1 study of Relapsed or Refractory Multiple Myeloma and Previously Treated Amyloid Light-chain (AL) Amyloidosis that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 180 participants, below the 324-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05652335, a Phase 1 study of Relapsed or Refractory Multiple Myeloma and Previously Treated Amyloid Light-chain (AL) Amyloidosis, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 1
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).

Conditions Studied

Relapsed or Refractory Multiple Myeloma Previously Treated Amyloid Light-chain (AL) Amyloidosis

Interventions

  • DRUG JNJ-79635322

Study Locations (20)

Other

  • UZ Antwerpen - Edegem
  • UZ Gent - Ghent
  • CHU de Liege - Liège
  • CHU Nantes - Nantes
  • CHU Lyon Sud - Pierre-Bénite
  • Chu Rennes Hopital Pontchaillou - Rennes
  • Institut Claudius Regaud - Toulouse
  • Japanese Red Cross Medical Center - Shibuya City
  • Osaka University Hospital - Suita-shi
  • The Cancer Institute Hospital of JFCR - Tokyo
  • VUMC Amsterdam - Amsterdam

California

  • City of Hope - Duarte
  • City of Hope Orange County Lennar Foundation Cancer Center - Irvine
  • University of California San Francisco - San Francisco

New York

  • Icahn School of Medicine at Mt. Sinai - New York
  • Memorial Sloan Kettering Cancer Center - New York

Colorado

  • Colorado Blood Cancer Institute - Denver

North Carolina

  • Levine Cancer Institute - Charlotte

Pennsylvania

  • University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine - Philadelphia

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2022-11-22
Est. Completion 2028-08-07
Phase Phase 1

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05652335

The ClinicalTrials.gov registry entry for NCT05652335 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (44% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which JNJ-79635322 is the first listed.

NCT05652335 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, New York.

Frequently Asked Questions

What is clinical trial NCT05652335 about?

NCT05652335 is a clinical study titled "A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis". The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansio...

What is the current status of trial NCT05652335?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2022-11-22. Estimated completion is 2028-08-07.

What conditions does trial NCT05652335 study?

This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis.

What interventions are being tested in trial NCT05652335?

The interventions under investigation include: JNJ-79635322 (DRUG).

Who is sponsoring clinical trial NCT05652335?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05652335 being conducted?

This trial has 20 study locations across California, Colorado, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed or Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Relapsed or Refractory Multiple Myeloma

All registered trials for this condition

Previously Treated Amyloid Light-chain (AL) Amyloidosis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.